GlassScriptPhysician profile
Mackenzie Difiore
NPI 1285202416
$10,649.71
in general payments reported to CMS, 2019-2025
32 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $2,159 · 2023: $2,922 · 2024: $3,655 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,976 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,975.99 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,517.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $920.29 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $871.84 | 2021-2025 | Xifaxan, Plenvu |
| Regeneron Healthcare Solutions, INC. | $829.49 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $793.78 | 2024-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $521.94 | 2021-2024 | Ocaliva |
| Genzyme Corporation | $421.38 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $411.10 | 2021-2025 | Linzess |
| Lilly USA, LLC | $281.74 | 2023-2025 | Omvoh |
| Evoke Pharma, INC. | $272.74 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $226.91 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $166.19 | 2022-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $159.63 | 2024-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $131.76 | 2024 | Voquezna |
| Pfizer INC. | $116.13 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $113.24 | 2022-2024 | Injectafer |
| Ardelyx, INC. | $111.64 | 2022-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $105.10 | 2024 | |
| Redhill Biopharma INC. | $89.74 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Ferring Pharmaceuticals INC. | $88.99 | 2024 | Rebyota, Clenpiq |
| Ipsen Biopharmaceuticals, INC | $82.88 | 2024 | Bylvay, Iqirvo |
| Madrigal Pharmaceuticals | $82.63 | 2024 | Rezdiffra |
| Celgene Corporation | $76.48 | 2023 | Zeposia |
| Qol Medical, LLC | $62.32 | 2023-2024 | Sucraid, Sucraid |
| Organon LLC | $45.21 | 2023-2025 | Hadlima |
| Fresenius Kabi USA, LLC | $29.82 | 2023 | |
| Braintree Laboratories, INC. | $23.17 | 2023 | Suflave, Sutab |
| Ethicon INC. | $21.94 | 2025 | Monarch Platform |
| Shield Therapeutics INC | $20.42 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.77 | 2024 | |
| Novo Nordisk INC | $17.42 | 2023 | Wegovy |
| Alnylam Pharmaceuticals INC. | $16.32 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Difiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.